BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roslind A, Johansen JS, Christensen IJ, Kiss K, Balslev E, Nielsen DL, Bentzen J, Price PA, Andersen E. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. Int J Cancer. 2008;122:857-863. [PMID: 17957792 DOI: 10.1002/ijc.23152] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Suh J, Kim S, Cho KS, Jung I, Cho WK, Jeon YJ, Jung MH, Suh BK. Urinary markers in the early stage of nephropathy in patients with childhood-onset type 1 diabetes. Pediatr Nephrol 2016;31:623-31. [DOI: 10.1007/s00467-015-3253-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Eurich K, Segawa M, Toei-Shimizu S, Mizoguchi E. Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells. World J Gastroenterol 2009; 15(42): 5249-5259 [PMID: 19908331 DOI: 10.3748/wjg.15.5249] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 56] [Article Influence: 4.2] [Reference Citation Analysis]
3 Krogh M, Christensen I, Bouwhuis M, Johansen JS, Nørgaard P, Schmidt H, Hansson J, Suciu S, Eggermont AM, Bastholt L; Nordic Melanoma Group and EORTC Melanoma Group. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma. Melanoma Res 2016;26:367-76. [PMID: 27076041 DOI: 10.1097/CMR.0000000000000237] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
4 Yang JD, Kim E, Pedersen RA, Kim WR, Pungpapong S, Roberts LR. Utility of Serum YKL-40 as a Tumor-Specific Marker of Hepatobiliary Malignancies. Gut Liver 2010;4:537-42. [PMID: 21253305 DOI: 10.5009/gnl.2010.4.4.537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
5 Peng C, Peng J, Jiang L, You Q, Zheng J, Ning X. YKL-40 protein levels and clinical outcome of human endometrial cancer. J Int Med Res 2010;38:1448-57. [PMID: 20926018 DOI: 10.1177/147323001003800427] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
6 Roslind A, Johansen JS. YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol 2009;511:159-84. [PMID: 19347297 DOI: 10.1007/978-1-59745-447-6_7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
7 Braakhuis BJ, Graveland AP, Dijk F, Ylstra B, van Wieringen WN, Leemans CR, Brakenhoff RH. Expression signature in peripheral blood cells for molecular diagnosis of head and neck squamous cell carcinoma. Oral Dis 2013;19:452-5. [PMID: 23034102 DOI: 10.1111/odi.12019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
8 Schultz NA, Johansen JS. YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel) 2010;2:1453-91. [PMID: 24281168 DOI: 10.3390/cancers2031453] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
9 Richter B, Roslind A, Hesse U, Nordling J, Johansen JS, Horn T, Hansen AB. YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis. Histopathology 2010;57:371-83. [PMID: 20840668 DOI: 10.1111/j.1365-2559.2010.03640.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
10 Yeo IJ, Lee CK, Han SB, Yun J, Hong JT. Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases. Pharmacol Ther 2019;203:107394. [PMID: 31356910 DOI: 10.1016/j.pharmthera.2019.107394] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 10.3] [Reference Citation Analysis]
11 Thöm I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS, Bokemeyer C, Schumacher U, Laack E. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer 2010;116:4114-21. [PMID: 20564116 DOI: 10.1002/cncr.25196] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
12 . Current world literature. Curr Opin Otolaryngol Head Neck Surg 2009;17:132-41. [PMID: 19363348 DOI: 10.1097/MOO.0b013e32832ad5ad] [Reference Citation Analysis]
13 Yang Y, Yang JJ, Tao H, Jin WS. YKL-40 and EGFR is a good biomarker for predicting nodal metastasis in anal carcinoma. Colorectal Dis 2014;16:69. [PMID: 23865791 DOI: 10.1111/codi.12357] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Høgdall EV, Ringsholt M, Høgdall CK, Christensen IJ, Johansen JS, Kjaer SK, Blaakaer J, Ostenfeld-Møller L, Price PA, Christensen LH. YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer 2009;9:8. [PMID: 19134206 DOI: 10.1186/1471-2407-9-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
15 Xing S, Zheng X, Zeng T, Zeng MS, Zhong Q, Cao YS, Pan KL, Wei C, Hou F, Liu WL. Chitinase 3-like 1 secreted by peritumoral macrophages in esophageal squamous cell carcinoma is a favorable prognostic factor for survival. World J Gastroenterol 2017; 23(43): 7693-7704 [PMID: 29209110 DOI: 10.3748/wjg.v23.i43.7693] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
16 Tarpgaard LS, Guren TK, Glimelius B, Christensen IJ, Pfeiffer P, Kure EH, Sorbye H, Ikdahl T, Yilmaz M, Johansen JS, Tveit KM. Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study. PLoS One 2014;9:e87746. [PMID: 24498368 DOI: 10.1371/journal.pone.0087746] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
17 Vom Dorp F, Tschirdewahn S, Niedworok C, Reis H, Krause H, Kempkensteffen C, Busch J, Kramer G, Shariat SF, Nyirady P, Rübben H, Szarvas T. Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer. J Urol 2016;195:1120-5. [PMID: 26454102 DOI: 10.1016/j.juro.2015.09.084] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
18 Bian B, Li L, Yang J, Liu Y, Xie G, Zheng Y, Zeng L, Zeng J, Shen L. Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies. Cancer Cell Int 2019;19:259. [PMID: 31624472 DOI: 10.1186/s12935-019-0983-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
19 Kjaergaard AD, Nordestgaard BG, Johansen JS, Bojesen SE. Observational and genetic plasma YKL-40 and cancer in 96,099 individuals from the general population. Int J Cancer 2015;137:2696-704. [PMID: 26095694 DOI: 10.1002/ijc.29638] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
20 Roslind A, Knoop AS, Jensen MB, Johansen JS, Nielsen DL, Price PA, Balslev E. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer. Breast Cancer Res Treat 2008;112:275-85. [PMID: 18157633 DOI: 10.1007/s10549-007-9870-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
21 Zhang W, Murao K, Zhang X, Matsumoto K, Diah S, Okada M, Miyake K, Kawai N, Fei Z, Tamiya T. Resveratrol represses YKL-40 expression in human glioma U87 cells. BMC Cancer. 2010;10:593. [PMID: 21029458 DOI: 10.1186/1471-2407-10-593] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
22 Zhu CB, Chen LL, Tian JJ, Su L, Wang C, Gai ZT, Du WJ, Ma GL. Elevated serum YKL-40 level predicts poor prognosis in hepatocellular carcinoma after surgery. Ann Surg Oncol. 2012;19:817-825. [PMID: 21861215 DOI: 10.1245/s10434-011-2026-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
23 Bi J, Lau SH, Lv ZL, Xie D, Li W, Lai YR, Zhong JM, Wu HQ, Su Q, He YL. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol. 2009;40:1790-1797. [PMID: 19765801 DOI: 10.1016/j.humpath.2009.07.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
24 Luo D, Chen H, Lu P, Li X, Long M, Peng X, Huang M, Huang K, Lin S, Tan L, Zhu Y, Chen Z, Ouyang N, Li H. CHI3L1 overexpression is associated with metastasis and is an indicator of poor prognosis in papillary thyroid carcinoma. Cancer Biomark 2017;18:273-84. [PMID: 28009325 DOI: 10.3233/CBM-160255] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
25 Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol 2009;5:1065-82. [PMID: 19792974 DOI: 10.2217/fon.09.66] [Cited by in Crossref: 96] [Cited by in F6Publishing: 106] [Article Influence: 7.4] [Reference Citation Analysis]
26 Mistrangelo M, Senetta R, Racca P, Castellano I, Chiusa L, Bellò M, Ricardi U, Morino M, Cassoni P. A novel biomarker-based analysis reliably predicts nodal metastases in anal carcinoma: preliminary evidence of therapeutic impact. Colorectal Dis 2013;15:1382-91. [PMID: 23692332 DOI: 10.1111/codi.12289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
27 Johansen JS, Bojesen SE, Mylin AK, Frikke-schmidt R, Price PA, Nordestgaard BG. Elevated Plasma YKL-40 Predicts Increased Risk of Gastrointestinal Cancer and Decreased Survival After Any Cancer Diagnosis in the General Population. JCO 2009;27:572-8. [DOI: 10.1200/jco.2008.18.8367] [Cited by in Crossref: 63] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
28 Su CW, Chen MK, Hung WC, Yang SF, Chuang CY, Lin CW. Functional variant of CHI3L1 gene is associated with neck metastasis in oral cancer. Clin Oral Investig 2019;23:2685-94. [PMID: 30341592 DOI: 10.1007/s00784-018-2683-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]